FTC Says Pharmacy Antitrust Amnesty Will Hurt Competition

Law360, New York (March 29, 2012, 2:32 PM EDT) -- A proposed law that would exempt independent pharmacies from antitrust laws and allow them to collectively negotiate with health plans would harm competition and raise the cost of prescription drugs for consumers, the Federal Trade Commission told a congressional panel Thursday.

A representative for the consumer protection agency said in a hearing before the U.S. House of Representatives Subcommittee on Intellectual Property, Competition and the Internet that a bill designed to give community pharmacies greater negotiation leverage would unfairly tilt the market and force prescription drug...
To view the full article, register now.